Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Ganetespib in Resectable Head and Neck Cancer
NCT02334319Phase 1Terminated
- Sponsor
- Emory University
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganetespib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Emory University. Primary endpoints: Change in expression of biomarkers in tissue samples at 24 months and Change in biomarker expression in blood samples at 24 months. Started Dec 2014; status: terminated.
02
Drugs
ganetespib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02334319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334319.